These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 1699088

  • 21. Efficacy of aprotinin with various anticoagulant agents in cardiopulmonary bypass.
    Terrell MR, Walenga JM, Koza MJ, Pifarré R.
    Ann Thorac Surg; 1996 Aug; 62(2):506-11. PubMed ID: 8694614
    [Abstract] [Full Text] [Related]

  • 22. In vitro effect of fresh frozen plasma on the activated coagulation time in patients undergoing cardiopulmonary bypass.
    Barnette RE, Shupak RC, Pontius J, Rao AK.
    Anesth Analg; 1988 Jan; 67(1):57-60. PubMed ID: 3257361
    [Abstract] [Full Text] [Related]

  • 23. [Effects of aprotinin on heparinized whole blood activated clotting time and whole blood prothrombin time].
    Wen Z, Zhu F, He X, Xiong S, He S.
    Hunan Yi Ke Da Xue Xue Bao; 1997 Jan; 22(4):304-6. PubMed ID: 9868081
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Celite and kaolin produce differing activated clotting times during cardiopulmonary bypass under aprotinin therapy.
    Feindt P, Seyfert UT, Volkmer I, Straub U, Gams E.
    Thorac Cardiovasc Surg; 1994 Aug; 42(4):218-21. PubMed ID: 7529949
    [Abstract] [Full Text] [Related]

  • 27. Clinical and biomaterial evaluation of hyaluronan-based heparin-bonded extracorporeal circuits with reduced versus full systemic anticoagulation in reoperation for coronary revascularization.
    Gunaydin S, Farsak B, McCusker K, Vijay V, Sari T, Onur MA, Gurpinar A, Zorlutuna Y.
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):135-42. PubMed ID: 19377380
    [Abstract] [Full Text] [Related]

  • 28. Guidelines for monitoring heparin by the activated clotting time when aprotinin is used during cardiopulmonary bypass.
    Hunt BJ, Segal HC, Yacoub M.
    J Thorac Cardiovasc Surg; 1992 Jul; 104(1):211-2. PubMed ID: 1377315
    [No Abstract] [Full Text] [Related]

  • 29. Increased anticoagulation during cardiopulmonary bypass by aprotinin.
    Levy JH, Salmenpera MT.
    J Thorac Cardiovasc Surg; 1991 Nov; 102(5):802. PubMed ID: 1719304
    [No Abstract] [Full Text] [Related]

  • 30. Aprotinin and hemostasis monitoring concerns during cardiac surgery.
    Swartz MF, Fink GW, Searles B.
    J Extra Corpor Technol; 2004 Dec; 36(4):375-83. PubMed ID: 15679283
    [Abstract] [Full Text] [Related]

  • 31. Effect of aprotinin on activated clotting time, whole blood and plasma heparin measurements.
    Despotis GJ, Joist JH, Joiner-Maier D, Alsoufiev AL, Triantafillou AN, Goodnough LT, Santoro SA, Lappas DG.
    Ann Thorac Surg; 1995 Jan; 59(1):106-11. PubMed ID: 7529483
    [Abstract] [Full Text] [Related]

  • 32. The effect of two different doses of aprotinin on hemostasis in cardiopulmonary bypass surgery: similar transfusion requirements and blood loss.
    Santamaría A, Mateo J, Oliver A, Litvan H, Murillo J, Souto JC, Fontcuberta J.
    Haematologica; 2000 Dec; 85(12):1277-84. PubMed ID: 11114135
    [Abstract] [Full Text] [Related]

  • 33. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting.
    Hertfelder HJ, Bös M, Weber D, Winkler K, Hanfland P, Preusse CJ.
    Semin Thromb Hemost; 2005 Dec; 31(4):426-40. PubMed ID: 16149021
    [Abstract] [Full Text] [Related]

  • 34. [Evaluation of adequate heparinization during artificial circulation in the framework of prolonged intraoperative administration of high doses of aprotinin].
    Dement'eva II, Charnaia MA, Shabalkin BV, Iavorovskiĭ AG, Piatnitskaia GKh.
    Anesteziol Reanimatol; 1994 Dec; (3):32-5. PubMed ID: 7521582
    [Abstract] [Full Text] [Related]

  • 35. Monitoring of anticoagulation in aprotinin-treated patients during heart operation.
    Tabuchi N, Njo TL, Tigchelaar I, Huyzen RJ, Boonstra PW, van Oeveren W.
    Ann Thorac Surg; 1994 Sep; 58(3):774-7. PubMed ID: 7524456
    [Abstract] [Full Text] [Related]

  • 36. Infusion of autologous platelet rich plasma does not reduce blood loss and product use after coronary artery bypass. A prospective, randomized, blinded study.
    Tobe CE, Vocelka C, Sepulvada R, Gillis B, Nessly M, Verrier ED, Hofer BO.
    J Thorac Cardiovasc Surg; 1993 Jun; 105(6):1007-13; discussion 1013-4. PubMed ID: 8501929
    [Abstract] [Full Text] [Related]

  • 37. Anticoagulation policy during use of aprotinin in cardiopulmonary bypass.
    van Oeveren W, van Oeveren B, Wildevuur CR.
    J Thorac Cardiovasc Surg; 1992 Jul; 104(1):210-1. PubMed ID: 1377314
    [No Abstract] [Full Text] [Related]

  • 38. Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation.
    Havel M, Teufelsbauer H, Knöbl P, Dalmatiner R, Jaksch P, Zwölfer W, Müller M, Vukovich T.
    J Thorac Cardiovasc Surg; 1991 Jun; 101(6):968-72. PubMed ID: 1710009
    [Abstract] [Full Text] [Related]

  • 39. Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass.
    Kawasuji M, Ueyama K, Sakakibara N, Tedoriya T, Matsunaga Y, Misaki T, Watanabe Y.
    Ann Thorac Surg; 1993 May; 55(5):1205-9. PubMed ID: 7684219
    [Abstract] [Full Text] [Related]

  • 40. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P, Kuitunen A, Petäjä J, Ilveskero S, Lassila R.
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.